R. Shimizu-hirota et al., Regulation of vascular proteoglycan synthesis by angiotensin II type 1 andtype 2 receptors, J AM S NEPH, 12(12), 2001, pp. 2609-2615
Recent studies have shown that proteoglycans play an important role in the
development of vascular disease and renal failure. In this study, the effec
ts of angiotensin II (AngII) type 1 (AT1) and type 2 (AT2) receptor stimula
tion on glycosaminoglycan and proteoglycan core protein synthesis in vascul
ar smooth muscle cells (VSMC) were examined. Treatment of AT1 receptor-expr
essing VSMC with An-II resulted in a dose-dependent and time-dependent incr
ease (2- to 4-fold) in H-3-glucosamine/S-35-sulfate incorporation, which wa
s abolished by pretreatment with the AT1 receptor antagonist, losartan. The
effects of AngII were inhibited by the epidermal growth factor receptor in
hibitor, AG1478, and the mitagen-activated protein kinase kinase inhibitor,
PD98059, but not the protein kinase C inhibitors, chelerythrine and stauro
sporine. AngII treatment also resulted in significant increases in the mRNA
of the core proteins, versican, biglycan, and perlecan. The effects of AT2
receptor stimulation were examined by retroviral transfection of VSMC with
the AT2 receptor. Stimulation of the AT2 receptor in these VSMC-AT2 cells
resulted in a significant (1.3-fold) increase in proteoglycan synthesis, wh
ich was abolished by the AT2 receptor antagonist, PD123319, and attenuated
by pretreatment with pertussis toxin. These results implicate both AT1 and
AT2 receptors in the regulation of proteoglycan synthesis and suggest the i
nvolvement of epidermal growth factor receptor-dependent tyrosine kinase pa
thways and G alphai/o-mediated mechanisms in the effects of the two recepto
rs.